Zentalis Pharmaceuticals (ZNTL) Jefferies Global Life Sciences Conference summary

Strategic overview and clinical focus

• Azenosertib, a WEE1 inhibitor, is positioned as a potential first-in-class therapy for Cyclin E1-positive platinum-resistant ovarian cancer (PROC), using a biomarker-driven approach to address significant unmet need.

• Recent clinical data show over 30% objective response rates at the primary dose, with durable responses (~6 months mDOR) and a manageable safety profile compared to standard chemotherapy.

• Interim data from over 200 PROC patients at 300mg and 400mg QD 5:2 dosing confirm efficacy and low rates of severe adverse events.

• Cyclin E1 biomarker, identified via proprietary IHC assay, captures a broader patient population than genetic amplification alone, with a companion diagnostic ready for registration studies.

• Financial runway extends into late 2027, with $332.5M cash as of March 31, 2025, supporting ongoing and future clinical development.

Market opportunity and competitive landscape

• Cyclin E1-positive PROC represents ~21,500 patients in the US and EU5, a large, underserved segment with no approved targeted therapies and poor outcomes on current chemotherapy.

• Cyclin E1+ status determined by IHC more than doubles the eligible patient pool compared to CCNE1 amplification alone.

• Mirvetuximab's success in folate receptor alpha-high patients demonstrates demand for biomarker-driven therapies; azenosertib aims to address the remaining population.

• Ongoing studies explore azenosertib in combination with bevacizumab for platinum-sensitive ovarian cancer and in other tumor types such as uterine serous carcinoma, HER2-positive solid tumors, breast, endometrial, and bladder cancers.

• The evolving landscape includes new ADCs and alternative biomarkers, but azenosertib is positioned for early-line use post-chemotherapy, with oral administration and favorable tolerability.

Regulatory and clinical development strategy

• Denali Part II phase two study is underway for potential accelerated FDA approval, with top-line data expected by end of 2026; a phase three confirmatory trial is planned to initiate in 2026.

• DENALI Part 2 will enroll ~100 patients, with endpoints including ORR, DOR, PFS, and safety; seamless enrollment and dose confirmation at interim analysis.

• Subgroup analyses suggest higher response rates and PFS in less heavily pretreated patients, supporting future trial confidence.

• The confirmatory phase three trial will randomize against standard of care, with design details pending FDA feedback expected in 2H 2025.

• Prospective patient selection uses the proprietary IHC cutoff, and azenosertib remains investigational and not yet approved by regulatory authorities.